Renalys Pharma Announces Completion Of Patient Enrollment In Registrational Phase III Clinical Trial Of Sparsentan For Iga Nephropathy In Japan
TOKYO, Jan. 30, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III ...